Aura Biosciences Inc AURA
π Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-29 |
| Shares Out. | 103,440,000 |
| Website | aurabiosciences.com/ β |
| Phone | 16175008864 |
| Employees | 113 |
| Net Income | -$33.7M |
| Free Cash Flow | -$91.6M |
| Total Assets | $137.7M |
| Total Liabilities | $30.4M |
| Equity | $107.2M |
About Aura Biosciences Inc
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Aura Biosciences Inc is a publicly traded company under the ticker symbol AURA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
12 analysts (2026-07-01)
